06 June 2023
The University of South Australia (UniSA) is taking its enterprising expertise to Boston, USA, this week as part of South Australia’s delegation to the BIO International Convention (BIO).
UniSA is the only university participating in the 16-organisation delegation led by the South Australian Government.
UniSA Deputy Vice-Chancellor Research and Enterprise, Professor Marnie Hughes-Warrington AO, says BIO provides a unique opportunity to showcase the University’s expertise in biomaterials engineering, pharmaceutical innovation, and research commercialisation to a global audience.
“As South Australia’s University of Enterprise, UniSA has an excellent track record in connecting industry with researchers and knowledge experts, and commercialising scientific research,” Prof Hughes-Warrington says.
“We have many state-of-the-art research laboratories and exceptional facilities for collaborating with industry. These include our Enterprise Hub, which provides a fantastic virtual and physical space. We are currently working with more than 2500 industry partners and are keen to build on our global connections at BIO.
“We will be highlighting the incredible work of our researchers and partners, with a focus on the capability within South Australia.”
The BIO event aims to promote the critical role of biotechnology and pharmaceutical science on a global stage and foster new partnerships to broker innovations with life-changing impact.
UniSA’s delegation will share its own capabilities in these disciplines and those that complement them – from cancer research, therapeutics, clinical trials and personalised medicine to advanced manufacturing and artificial intelligence. This includes cutting-edge research in diverse areas such as using Australian Indigenous native plant extracts to reduce anti-inflammatory activity, and reducing antimicrobial resistance in humans, animals and plants.
UniSA has commercialised more than 130 research innovations, including technology licencing deals and the creation of spin-out companies. These include spin-out companies Cincera, which aims to treat inflammatory and fibrotic conditions by blocking key enzymatic targets, reducing inflammatory impacts on peripheral tissues in the process, and Ferronova, which is developing a new cancer device to accurately identify sentinel lymph nodes for management of solid tumours.
UniSA’s Enterprise Hub works with organisations across 13 industry sectors to help them reach their commercial goals, drawing on its researchers, industry partnerships, and the experts in UniSA’s commercialisation arm.
…………………………………………………………………………………………………………………………
Media contact: Megan Andrews M: +61 434 819 275 E: Megan.andrews@unisa.edu.au
